Immutep Limited IMMP
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +6.99%
- 1 year
- +59.38%
- Open
- 3.30
- Prev close
- 3.33
- Mkt cap
- 22.55M
- Vol
- 10.59K
- Avg vol
- 16.17K
- EPS
- -7.30
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.05
- High
- 3.30
- Forward P/E
- -7.33
- Beta
- 1.92
- Short ratio
- 42.18
- Inst. own
- 6.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 5, 2023
- 50-d avg
- 2.00
- 200-d avg
- 2.32
- 1y target
- 9.50
Key statistics
- Market cap
- 294.00M
- Enterprise value
- 2.77B
- Trailing P/E
- 0.00
- Forward P/E
- -7.33
- PEG ratio
- 0.00
- Price / sales
- 76.53
- Price / book
- 15.23
- EPS (TTM)
- -0.25
- Beta
- 1.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.84M
- Revenue growth
- -4.90%
- Free cash flow
- -23.25M
- Total cash
- 181.88M
- Total debt
- 1.59M
- Return on equity
- -26.21%
- Shares outstanding
- 145.46M
- Short % of float
- 3.56%
- 50-day average
- 2.00
- 200-day average
- 2.32
Analyst view
Consensus: strong buy
- Target (low)
- 7.00
- Target (mean)
- 9.50
- Target (high)
- 12.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 5, 2023
Expected Oct 5, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 5, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Sep 7, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| Sep 2, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| Aug 27, 2019 | Jun 1, 2019 | 0.00 | — | — | — |
| Sep 4, 2018 | Jun 1, 2018 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Baird | main | Outperform | Outperform |
| Jun 27, 2024 | Baird | main | Outperform | Outperform |
| May 17, 2024 | Capital One | init | — | Overweight |
| Aug 28, 2023 | Baird | reit | Outperform | Outperform |
| Aug 3, 2023 | Baird | init | — | Outperform |
| Aug 2, 2023 | Baird | init | — | Outperform |
About Immutep Limited
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- immutep.com
News
- Immutep Refocuses Efti Development On HNSCC, Soft Tissue Sarcoma; New Trial Starts Targeted For H2 2027
- Immutep Receives Cash Payment Of €1.36M From French Government Under Tax Incentive Program
- Immutep Presents ePoster At European Society For Medical Oncology Congress 2026 For Its Eftilagimod Alfa In Combination With KEYTRUDA
- Prima BioMed (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average – What’s Next?
- Immutep Receives A$652,248 Grant From Monash University Under Australian Research Council's Linkage Projects Scheme For Research Collaboration
- Immutep Receives A$856,669 Cash Rebate From Australian Federal Government’s R&D Tax Incentive Program
- Immutep Receives ~A$0.86 Million R&D Tax Incentive
- Immutep Changes ADS Ratio From One ADS Representing 10 Shares To One ADS Representing 200 Shares, Effective September 28
- Short Interest in Prima BioMed Ltd (NASDAQ:IMMP) Decreases By 36.4%
- Prima BioMed (NASDAQ:IMMP) Stock Crosses Above 50 Day Moving Average – Should You Sell?
Your note
Sign in to keep a note on IMMP — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 0.62% | 908,141 | 1.80M | Sep 29, 2024 |
| Meridian Wealth Management, LLC | 0.27% | 398,450 | 788.93K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.08% | 112,503 | 222.75K | Sep 29, 2024 |
| XY Capital Ltd | 0.07% | 108,349 | 214.53K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.06% | 80,489 | 159.37K | Sep 29, 2024 |
| Pfg Investments, LLC | 0.04% | 51,000 | 100.98K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Biotechnology ETF | 0.60% | 875,877 | 1.73M | Oct 30, 2024 |
| Trust for Professional Managers-ActivePassive International Equity ETF | 0.08% | 117,969 | 233.58K | Aug 30, 2024 |
| Brighthouse Fds Tr II-BH/Dimensional International Small Co Port | 0.01% | 8,886 | 17.59K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 18,722 | 37.07K | Oct 30, 2024 |
| DFA Asia Pacific Small Company Series | 0.00% | 7,245 | 14.35K | Jul 30, 2024 |
| DFA International Sustainability Core 1 Portfolio | 0.00% | 4,300 | 8.51K | Jul 30, 2024 |